Why It Matters
The American College of Clinical Pharmacy (ACCP) filed its report for the third quarter of 2026 on Medicare and other public health program coverage for direct patient care by qualified pharmacists, medication therapy management services (MTMS) under Medicare Part D, medication safety, Medicare funding for specialized residency training, and interactions with the Agency for Healthcare Research and Quality (AHRQ) on MTMS quality.
By the Numbers
The in-house third-quarter 2026 filing reports $144,981, unchanged from the second-quarter 2026 in-house report. In the second quarter of 2026, ACCP also retained Capitol Advocacy & Government Affairs LLC (Capitol Advocacy), which filed a separate $450,000 report, bringing that quarter's client total to $594,981. The third-quarter 2025 client total was also $594,981, combining the same in-house amount with a $450,000 Capitol Advocacy filing.
The filing names two lobbyists: John McGlew, Senior Director of Government Affairs, and Kathy Pham, Senior Director, Policy and Professional Affairs.
Broader Context
In May 2025, H.R. 3164, the Ensuring Community Access to Pharmacist Services Act, was introduced in the House; it would provide Medicare coverage for specified pharmacist testing and treatment services.
In April 2025, the Centers for Medicare and Medicaid Services (CMS) issued its Contract Year 2026 Medicare Advantage and Part D final rule, deferring to later rulemaking a proposal to expand the list of core services in Part D MTMS programs.
The Bottom Line
The American College of Clinical Pharmacy reported $144,981 in in-house lobbying spending in each quarter from the second quarter of 2025 through the third quarter of 2026. Capitol Advocacy & Government Affairs LLC reported $450,000 each quarter from the first quarter of 2025 through the second quarter of 2026, and it has no third-quarter 2026 report.
Access the Legis1 platform for comprehensive political news, data, and insights
Spot something wrong? Report an issue with this article